Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis Ruchika Sharma7 Feb 2025 11:30 AM ISTBengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global biopharmaceutical company, have...
Prove efficacy of Itolizumab for subcutaneous route: CDSCO panel Tells Biocon Biologics Dr. Divya Colin13 Sept 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major Biocon...
Biocon in collaboration with Equillium begins Itolizumab clinical study for Ulcerative Colitis in India Ruchika Sharma15 Dec 2022 5:00 PM ISTItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6- ALCAM pathway, which can drive several...
Role of Itolizumab in the Treatment of COVID-19 Patients in ICU Patients Dr. Nandita Mohan28 Oct 2022 9:30 AM ISTCovid variants are mutating and are still a global threat, irrespective of the type of variant and its replication potential, the cytokine storm,...
Biocon arm gets DCGI nod to initiate clinical study for Itolizumab Ruchika Sharma24 Dec 2021 1:13 PM ISTItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway.
Revise Itolizumab phase 3 study protocol for Covid-19: CDSCO panel tells Biocon Medical Dialogues Team13 Sept 2021 5:26 PM ISTNew Delhi: After reviewing Biocon's Phase III trial protocol for Itolizumab for treating Covid-19 patients, the Subject Expert Committee (SEC)...
Biocon to furnish more data for consideration of Itolizumab in treating COVID patients Farhat Nasim29 July 2020 4:24 PM ISTBengaluru: After facing rejection from the Health Ministry, Bengaluru-based drugmaker Biocon is now preparing to present 'more data' for consideration...
Setback to Biocon: Health Ministry Says NO To Psoriasis Drug Itolizumab In Clinical Management Protocols For COVID-19 Ruchika Sharma27 July 2020 3:59 PM ISTNew Delhi: In a major setback to drug major, Biocon, the National Task Force on COVID-19 has decided against including Itolizumab drug in clinical...
CONTROVERSY: DCGI exempts Biocon from Phase 3 trial of COVID drug Itolizumab, ICMR sees red Farhat Nasim17 July 2020 4:21 PM ISTBengaluru: In a major controversy, the exemption of biotechnology major Biocon from conducting Phase 3 trials of its psoriasis drug...
Biocon Itolizumab gets DCGI nod to treat COVID-19 patients Ruchika Sharma13 July 2020 1:28 PM ISTItolizumab will be manufactured and formulated as an intravenous injection at Biocon’s bio-manufacturing facility at Biocon Park, Bengaluru.
COVID Cure: DCGI approves Itolizumab for restricted emergency use Ruchika Sharma11 July 2020 2:43 PM ISTIt is for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
